Immunitybio announces launch of phase 2 trial of il-15 superagonist anktiva with antiretroviral therapy to inhibit hiv reservoirs

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced that the u.s. military hiv research program (mhrp) at the walter reed army institute of research has launched a phase 2 clinical trial in thailand to evaluate immunitybio's interleukin-15 (il-15) superagonist anktiva® (also called n-803) administered in combination with antiretroviral therapy (art) during acute hiv infection as an experimental therapy to target and inh
IBRX Ratings Summary
IBRX Quant Ranking